The Deal
Sunday, November 22, 
6:05 am


Boston Scientific Corp.

Posted on September 12, 2008 at 4:44 PM
Filed under: Most Admired
[ Share ]  [ E-mail ]  [ Leave a Comment ]
BostonScientificLogo.jpgBoston Scientific Corp. develops, manufacture and markets medical devices that are used in various interventional medical specialties worldwide. The company offers its products in three groups: Cardiovascular, endosurgery and neuromodulation. The company was founded in 1979 and has its headquarters in Natick, Mass.

To participate in the Most Admired Corporate Dealmakers Survey, go to www.thedeal.com/cdsurvey

See the complete list of healthcare companies

Boston Scientific Corp.

Acquisitions
Date
Target
Acquirer
Price ($mill.)
3/26/08
CryoCor Inc. Boston Scientific Scimed Inc.
(Parent: Boston Scientific Corp.)
$18
12/5/05
Guidant Corp. Boston Scientific Corp.
26,899
4/17/07
Celsion Corp.
(Prolieve assets)
Boston Scientific Corp.
60
Total
$26,977
 
Divestitures
Date
Target
Seller
Price ($mill.)
11/5/07
Boston Scientific Corp.
(Cardiac surgery and vascular surgery businesses)
Boston Scientific Corp.
$750
12/13/07
Boston Scientific Corp.
(Fluid management and venous access businesses)
Boston Scientific Corp.
415
3/31/08
Boston Scientific Santa Rosa Corp. Boston Scientific Corp.
30
Total
$1,195

Sources: Standard & Poor's Capital IQ, The Deal


Join Corporate Dealmaker's LinkedIn forum

Comments
Post a comment


Search


Search For

Corporate Dealmaker Video


Deal Economy 2010: Avaya's Ali on digesting Nortel

Avaya Inc.'s Mohamad Ali on the company's next target.
Decade of The Deal


Movers & Shakers


Juergen Lasowski
Onyx Pharmaceuticals Inc.

Edward Swallow
Northrop Grumman Corp.

Owen Mahoney
Outspark

Alice Kim
FLO TV Inc.

Eric Hausler
Isle of Capri Casinos Inc.
Juergen Lasowski, Onyx Pharmaceuticals Inc.
Edward Swallow, Northrop Grumman Corp.
Owen Mahoney, Outspark
Alice Kim, FLO TV Inc.
Eric Hausler, Isle of Capri Casinos Inc.


COMPLETE MOVERS & SHAKERS ARCHIVES

The Magazine


MACDdec1cover.gifAnd the winners are...
Even in a period when things like toxic credit default swaps and noxious structured investment vehicles dominate the conversation in many parts of the deal community, people are still willing to take the time to recognize skill and achievement in the strategic transactions that help those companies adapt and grow.
View the complete issue


Last Issue
Archives
Suggest a topic
Purchase a reprint
Subscribe to The Deal


Monthly Archives


Syndicate

Contributors

footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg


©Copyright 2009, The Deal, LLC. All rights reserved. Please send all technical questions, comments or concerns to the Webmaster.